Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy…
Articles by Marisa Horak, MS
November is National Alzheimer’s Awareness Month, and the Alzheimer’s Foundation of America (AFA) is encouraging those impacted by…
Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other…
Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate…
The U.S. Food and Drug Administration (FDA) has approved the oral therapy Zunveyl (benzgalantamine), previously known as…
The safety and effectiveness of oral therapy candidate buntanetap are comparable in people with early Alzheimer’s disease regardless…
The U.S. Food and Drug Administration (FDA) has agreed to review a supplemental application seeking authorization of once-monthly maintenance dosing…
An advisory committee to the U.S. Food and Drug Administration (FDA) has unanimously voted in favor of donanemab, an…
Eisai has started a rolling application seeking U.S. approval of a subcutaneous, or under-the-skin, injection version of Leqembi…
A U.S. Food and Drug Administration (FDA) advisory committee will meet June 10 to review clinical trial data related to…